• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 24th November 2015

How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework. Real world data (RWD) is a term that is becoming increasingly widespread in health economics and health…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
24-Nov-Lilly-RWE-blog-V2

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.

Real world data (RWD) is a term that is becoming increasingly widespread in health economics and health services research – with good reason. RWD is information that can be used for health care decision-making which is collected outside of an experimental clinical trial setting. RWD therefore has the benefit of reflecting outcomes in the “real-world”, i.e. routine clinical practice. 

The environment for collecting data alongside clinical practice and using it to support decision-making by regulators and payers is changing. Regulatory flexibilities and increasing public pressure to facilitate earlier access to medicines (e.g. through adaptive pathways or early access schemes) means that regulators are increasingly monitoring benefits and risks throughout a medicine’s lifecycle; RWD is essential to support this. 

Payers are similarly being challenged to conduct earlier value assessments under greater uncertainty, and re-visiting assessments as further RWD is collected. Moreover, managed entry agreements and arrangements for performance-based payments require data to be collected alongside clinical practice. These themes are central to the Accelerated Access Review currently being conducted by the UK’s Department of Health. 

Supporting all of these developments is the improving infrastructure across the globe for data collection, for example through electronic health records. However, in order to utilise and derive value from RWD, appropriate and facilitative information governance is essential. RWD becomes real world evidence (RWE) – what is really of value to stakeholders – after a series of activities which facilitate the transformation of raw data into analysis and results. Robust and proportionate data governance, applied at each step, is essential in realising the value of RWD. 

Figure 1: Value chain for generating Real World Evidence

OHE Consulting has just published a Consulting Report, commissioned by Lilly, which assesses the core governance arrangements for how RWD (both routinely-collected and de-novo) is accessed or generated, and used credibly to provide evidence in eight countries: the UK, France, Italy, Sweden, Germany, the Netherlands, Australia and the U.S. In our recommendations we focus on the first four steps of the value chain set out in Figure 1. By analysing the current state-of-play in each country, we propose an aspirational governance framework that could guide the management of data access and use, and facilitate constructive interactions among the relevant stakeholders. 

Governance arrangements for health data have at their core the need to balance public and privacy interests, of advancing our understanding of medical treatments through evaluation and research, on the one hand, and protecting individuals’ privacy, on the other. Different countries have different ways of addressing this aim. In most cases the legal framework in place to protect patient data is not completely prescriptive, making a clear governance framework all the more important. 

We find that appropriate and facilitative information governance, along with public trust, is key to realising the benefits of scientific research. Along with sophisticated and transparent approaches to data linkage, patient consent has a key role to play, alongside mechanisms for anonymisation and authorisation. For example, where data collection is on a routine basis across a large patient cohort, an opt-out system of patient consent may be appropriate. Data can be de-identified by removing any personally identifiable information and replacing the unique patient identifier with a pseudonym. 

By outlining the individual aspects and actions of an ideal framework for data governance, the authors assess the extent to which each of the countries analysed currently meets these criteria. The resulting set of recommendations work towards setting out international standards for a more facilitative environment for the transformation of RWD into RWE.

Access the full report here.

For more information contact Amanda Cole at OHE.

  • Drug Development/R&D
  • Economics of Innovation
  • Consulting Reports

Related News

  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!